ROR1 and cancer: With ROR1-targeted therapy already showing promising signs of activity in various cancer types, KAN0441571C brings the added benefits of being a small molecule inhibitor that directly inhibits the tyrosine kinase domain of a selectively overexpressed kinase, ROR1.